Summary
Cynata Therapeutics Limited (CYP) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cynata Therapeutics Limited ever had a stock split?
Cynata Therapeutics Limited Profile
| Biotechnology Industry | Healthcare Sector | Kilian Kelly CEO | ASX Exchange | Q3079W119 CUSIP |
| AU Country | 2 Employees | - Last Dividend | 30 Oct 2013 Last Split | - IPO Date |
Overview
Cynata Therapeutics Limited, operating within Australia, is at the forefront of developing and commercializing innovative stem cell technologies aimed at human therapeutic use, specifically through its proprietary Cymerus brand. This brand leverages cutting-edge induced pluripotent stem cell and mesenchymal stem cell technology to address a broad spectrum of diseases. Initially known as Eco Quest Limited, the company underwent a name change to Cynata Therapeutics Limited in October 2013. Since its inception in 2003, it has been committed to advancing stem cell treatment, underlining its dedication through a strategic partnership with Fujifilm, which focuses on the clinical and commercial manufacturing, as well as supply of Cynata’s therapeutic mesenchymal stem cell products.
Products and Services
- CYP-001
This leading therapeutic product candidate of Cynata has successfully completed Phase I clinical trials, showcasing its potential in the treatment of graft versus host disease. This promising development indicates Cynata’s capability in addressing complex post-transplant complications using stem cell technologies.
- CYP-004
Currently in Phase III clinical trial, CYP-004 is being developed as a groundbreaking treatment for osteoarthritis. This underscores Cynata’s dedication to tackling prevalent, debilitating conditions through advanced stem cell therapy solutions.
- CYP-006TK
This novel product is a polymer-coated silicon wound dressing specifically designed for diabetic wounds, representing Cynata’s innovative approach to wound care and its commitment to improving outcomes for patients with diabetes-related complications.
- Other Developments
Alongside its primary candidates, Cynata is also pushing the boundaries in stem cell therapy by developing treatments for a wide array of conditions including asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. These efforts reflect the broad applicability of Cynata’s Cymerus technology across different medical fields, underscoring the company's role in potentially revolutionizing the healthcare landscape.
